OXFORD BIOMEDICA

OXFORD BIOMEDICA

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products und... er development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Oxford BioMedica_logo

Industry:
Company

Founded:
1995

Address:
Windrush Court, Oxford, United Kingdom Zipcode OX4 6LT

Country:
United Kingdom

Phone:
44 1865 783 000

Market Cap:
848.77M
Total Revenue:
64.06M
Total Assets:
122.93M
Total Cash:
16.24M

Parent organization: Novo Holdings A/S


Key Executives
Name Title Pay Year Born
Mr. John Dawson CEO & Exec. Director 834,000$ 1960(60 years old)
Mr. Stuart Paynter CFO, Company Sec. & Director 476,000$ 1973(47 years old)
Mr. Nick Page Chief Operations Officer N/A N/A
Dr. James Miskin Ph.D. Chief Technical Officer N/A N/A
Dr. Kyriacos Mitrophanous Ph.D. Chief Scientific Officer N/A N/A
Ms. Catherine Isted Head of Corp. Devel. & IR N/A N/A
Ms. Natalie Louise Walter Gen. Counsel N/A N/A
Ms. Sarah Macleod Head of Communications N/A N/A
Ms. Helen Stephenson-Ellis Chief People Officer N/A N/A
Dr. Richard Harrop D.Phil. B.Sc. Head of Clinical Analysis N/A N/A



Financial & Stock
Exchange LSE. Currency in GBp. Market state PREPRE
According to Oxford BioMedica's financial reports the company's revenue in 2019 were 64.06M an decrease(-3.03%) over the years 2018 revenue that were of 66.78M. In 2019 the company's total earnings were -16.07M while total earnings in 2018 were 7.54M(-328.57%).
Company's stock symbol is OXB.L. Lastest price : 1,030.00. Total volume :90.47k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.oxb.com

  • Host name: ip-132-148-148-32.ip.secureserver.net
  • IP address: 132.148.148.32
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...
Loading ...


More informations about "Oxford BioMedica" on Search Engine

OxfordBiomedica

Oxb.com Oxford Biomedica plc Windrush Court Transport way Oxford OX4 6LT United Kingdom +44 (0) 1865 783 000. Contact Us

OxfordBiomedica

Oxb.com News & events | OxfordBiomedica. Oxford Biomedica plc Windrush Court Transport …

OxfordBiomedica

Oxb.com Oxford Biomedica is working on the regulatory approval for a planned three cohort phase …

OxfordBiomedica

Oxb.com At Oxford Biomedica, we support you to get to where you want to be, wherever that might …

OxfordBiomedica

Oxb.com Shareholder meetings, circulars & prospectuses ...

OxfordBiomedica

Oxb.com Multimedia | OxfordBiomedica. Oxford Biomedica plc Windrush Court Transport …

OxfordBiomedica

Oxb.com Investors | OxfordBiomedica. Oxford Biomedica plc Windrush Court Transport way Oxford …

OxfordBiomedica

Oxb.com Oxford Biomedica is committed to its role as a responsible business and the Group has …

OxfordBiomedica

Oxb.com Oxford Biomedica has developed and optimised analytics required for product …

OxfordBiomedica

Oxb.com Bioprocessing | OxfordBiomedica. Oxford Biomedica plc Windrush Court Transport …

Oxford BioMedica - Wikipedia

En.wikipedia.org Oxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

OXFORD BIOMEDICA (OXBDF) Stock Price, News, Quote

Finance.yahoo.com Professor Dame Kay Davies, incoming Non-Executive Director of Oxford Biomedica, said: “Oxford Biomedica is a world leader in cell and gene therapy, a field which my research has been closely...

Oxford Biomedica Signs New 3-Yr Development & Supply Deal

Nasdaq.com Apr 06, 2021 · (RTTNews) - Oxford Biomedica plc. (OXB.L), a gene and cell therapy group, announced Tuesday that it has signed a new three year Development & Supply Agreement or DSA with German Pharmaceutical ...

Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has

Finance.yahoo.com Dec 30, 2020 · Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in …

Oxford Biomedica: Sanofi To Terminate Collaboration And

Nasdaq.com Mar 19, 2021 · (RTTNews) - Oxford Biomedica plc. (OXB.L), a gene and cell therapy group, announced Friday that French drug maker Sanofi (SNYNF, SNY) has given notice that they intend to terminate the...

Oxford Biomedical Technologies, Inc.

Nowleap.com Oxford Biomedical Technologies, Inc. is a Federally and State of Florida licensed medical reference laboratory.

Oxford Biomedica | FiercePharma

Fiercepharma.com Dec 08, 2020 · Oxford Biomedica Oxford BioMedica has been a key manufacturing partner for AstraZeneca and the University of Oxford for their adenovirus-based COVID-19 shot.

Inside Oxford’s coronavirus vaccine development

Theguardian.com Dec 21, 2020 · Oxford Biomedica is manufacturing tens of millions of doses of the vaccine on behalf on AstraZeneca. Production involves various stages, starting with a vial of a frozen master bank of cells ...

OXB Share Forecast, Price & News (Oxford Biomedica)

Marketbeat.com Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000.

Oxford Biomedica - In a cell and gene therapy sweet spot

Edisongroup.com Jun 04, 2019 · Oxford Biomedica is a research client of Edison Investment Research Limited Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVV), a critical component of cell and gene therapies (CGT).

Oxford Biomedica plc: Board Changes London Stock Exchange:OXB

Globenewswire.com Feb 03, 2021 · Oxford Biomedica (LSE: OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases.

AstraZeneca shells out up to $60M to reserve more

Fiercepharma.com Sep 01, 2020 · Oxford Biomedica will set aside space in three manufacturing suites at its growing, 84,000-square-foot Oxbox facility through 2021. The initial 18 …

Oxford Biomedica | Share Price, Company News & Analysis

Edisongroup.com Mar 31, 2021 · Oxford Biomedica (OXB) is a global leader in lentiviral development and manufacturing. It is expanding its manufacturing facilities through Oxbox, a 84,000 sq ft state-of-the-art bioprocessing facility, significantly increasing its production capacity to match increasing demand and to continue growing its platform revenues.

Oxford Biomedica (LSE:OXB) - Share price, News & Analysis

Simplywall.st Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally.

Oxford Biomedica says Sanofi pulling out of haemophilia

Sharecast.com Mar 19, 2021 · Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.

OXFORD BIOMEDICA PLC OXB Stock | London Stock Exchange

Londonstockexchange.com OXFORD BIOMEDICA PLC OXB Company page - Search stock, chart, recent trades, company information, trading information, company news, fundamentals

Oxford Biomedica shares soar after Covid vaccine boost

Msn.com Oxford Biomedica teamed with Astra in May to produce the vaccine and said today it could get an additional $35 million plus other costs until the end of 2021 under the new 18-month deal.

Oxford Biomedica - AnnualReports.com

Annualreports.com Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life-changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners.

Oxford BioMedica Market Cap | OXBDF

Ycharts.com Oxford Biomedica inks R&D pact with Papyrus Therapeutics for gene therapy for cancer SA Breaking News 09/17 12:01 ET. Oxford BioMedica reports 1H results SA Breaking News 09/17 05:32 ET. Oxford Biomedica inks COVID-19 vaccine supply deal with AstraZeneca SA Breaking News 09/01 07:20 ET.

Ex-Trader Stephen Diggle Bets Big on Oxford’s Tiny Vaccine

Bloomberg.com Aug 04, 2020 · Oxford Biomedica Plc. While few had heard of the gene and cell therapy company before 2020, its stock has been given an extra boost since joining a consortium to produce the University of Oxford’s

Oxford BioMedica - Home | Facebook

Facebook.com Oxford BioMedica June 14, 2019 · We're hugely proud to have won the award for Best Technology at last night's European Mediscience Awards. Here's our CEO John Dawson collecting our trophy last night.

Did Oxford Biomedica just find a new treatment for

Fool.co.uk Oct 30, 2020 · As a reminder, Oxford Biomedica is a gene and cell therapy biotechnology company. Using its proprietary LentiVector platform, the firm collaborates …

Oxford Biomedica | LinkedIn

Linkedin.com Oxford Biomedica | 18,728 followers on LinkedIn. Delivering life-changing gene therapies to patients | Oxford BioMedica (OXB) is a leading gene and cell therapy group focused on developing life ...

OXB:London Stock Quote - Oxford Biomedica PLC - Bloomberg

Bloomberg.com Oxford Biomedica is a gene and cell therapy group focused on developing treatments for serious diseases based around its FDA approved lentiviral vector delivery platform. The Company leverages ...

Oxford Biomedica Share Price. OXB - Stock Quote, Charts

Uk.advfn.com Jul 06, 2020 · Oxford Biomedica Daily Update: Oxford Biomedica Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 1,010p. Oxford Biomedica Plc has a 4 week average price of 935p and a 12 week average price of 894p.

Oxford Biomedica Signs Five Year Collaboration Agreement

Globenewswire.com Jun 08, 2020 · About Oxford Biomedica Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases.Oxford Biomedica ...

Oxford Biomedica (OXB) | The Share Centre

Share.com Oxford Biomedica Order ref: XXXXXX. Valued at 9:28pm on 11 April 2021 using (at least) 15 minute delayed prices. The market is currently closed. Your purchase will be made at the next opportunity. View pending investments. View account. Duplicate order You …

AstraZeneca picks Oxford Biomedica to make potential COVID

Reuters.com Oxford Biomedica’s shares closed 6.6% higher at 764 pence. Separately, GSK, the world’s largest vaccine maker, laid out plans to produce 1 billion doses of vaccine efficacy boosters for COVID ...

Oxford Biomedica Mission, Benefits, and Work Culture

Uk.indeed.com Oxford BioMedica's gene-based medicine capabilities cover the entire product lifecycle; from pre-clinical development, to regulatory support, to all future stages of viral vector product clinical development and commercial scale. We recognise the importance of strong relationships and industry alliances in delivering success.

Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors

Genengnews.com Feb 15, 2018 · Oxford BioMedica said today it will partner with Bioverativ to develop and manufacture lentiviral vectors designed to treat hemophilia, through a collaboration that could generate up to $105 ...

Oxford Biomedica Plc Share Chat - Chat About OXB Shares - OXB

Uk.advfn.com Jul 06, 2020 · Oxford Biomedica Share Chat (OXB) Follow OXB. Buy. Sell. Share Name Share Symbol Market Type Share ISIN Share Description; Oxford Biomedica Plc: LSE:OXB: London: Ordinary Share: GB00BDFBVT43: ORD 50P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade -4.00-0.4%: 1,006.00: 1,008.00 ...

Liberum Capital Reiterates “Buy” Rating for Oxford

Themarketsdaily.com Apr 08, 2021 · Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell …

Papyrus Therapeutics Inc. Signs Research Collaboration

Businesswire.com Sep 17, 2020 · About Oxford Biomedica . Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford ...

Oxford Biomedica partners VMIC for vaccine manufacturing

Pharmaceutical-technology.com Apr 08, 2021 · Oxford Biomedica and VMIC are members of the Oxford University manufacturing consortium formed to scale-up the production of Covid-19 vaccine candidate, AZD1222. AstraZeneca is responsible for the manufacturing, development and distribution of the vaccine candidate globally. Last month, the pharmaceutical giant signed an initial clinical and ...

Oxford Biomedica Jobs - 2021 | Indeed.com

Uk.indeed.com Oxford Biomedica’s Manufacturing, Science and Technology Team is responsible for process and technology development activities from early concept through …

PhoreMost and Oxford Biomedica collaborate to develop next

News-medical.net Nov 10, 2020 · PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, …

Oxford BioMedica PLC, OXB:LSE forecasts - FT.com

Markets.ft.com The 8 analysts offering 12 month price targets for Oxford BioMedica plc have a median target of 1,100.00, with a high estimate of 1,450.00 and a low estimate of 580.00. The median estimate represents a 9.34% increase from the last price of 1,006.00.

Oxford Biomedica eyes UK supply boost of AstraZeneca's

Reuters.com Oxford Biomedica has signed a new manufacturing agreement with a group backed by the UK government to help it scale up production of AstraZeneca's …

Oxford BioMedica Company Profile: Stock Performance

Pitchbook.com Oxford BioMedica General Information Description. Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focusses on the field of immunotherapy by managing a platform of technologies in designing gene-based medicines.

OXB–203 | OxfordBiomedica

Oxfordbiomedica.com OXB-203Gene therapy for wet age-related macular degenerationWet age-related macular degeneration (AMD)AMD is a common cause of vision loss. It affects an estimated 25 – 30 million people worldwide with the incidence expected to triple by 2025. The “wet” form of the condition accounts for 10 – 15% of all cases, and 90% of those with severe loss of vision.Our approach OXB-203 is

Leading by example: how AquaBounty, Oxford Biomedica, and

Synbiobeta.com Oct 07, 2019 · The partnerships bring income to Oxford Biomedica while making it possible for Novartis and others to have a reliable, stable source of material. By Stan Zurek – Own work, CC BY-SA 3.0 “Oxford Biomedica is now the world’s largest provider of viruses for selling gene therapy,” says Hallinan.

Oxford Biomedica signs a new three year Development

Markets.businessinsider.com Apr 06, 2021 · About Oxford Biomedica Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases.

Talk:Oxford BioMedica - Wikipedia

En.wikipedia.org In October 2014, Oxford BioMedica announced a second partnership with Novartis for the non-exclusive development and commercialisation licence in oncology under Oxford BioMedica’s LentiVector® platform. Under this agreement, Oxford BioMedica manufactures lentiviral vectors expressing the gene therapy CTL019/CART-019 [Link].

Oxford BioMedica PLC, OXB:LSE historical prices - FT.com

Markets.ft.com Latest Oxford BioMedica PLC (OXB:LSE) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.